ArticleInternational journal of retina and vitreous2021
Argus II retinal prosthesis for retinitis pigmentosa in the Middle East: The 2015 Pan-American Association of Ophthalmology Gradle Lecture.
Article in International journal of retina and vitreous, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00407602 (Argus® II Retinal Stimulation System Feasibility Protocol), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Argus® II Retinal Stimulation System Feasibility Protocol
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Determinants of spatial resolution in retinal prostheses: understanding the gap between geometry and vision.Biomedical engineering letters · 2026Review
- Motion perception with visual prostheses.Progress in biomedical engineering (Bristol, England) · 2026Review
- Multi-Level Perception Systems in Fusion of Lifeforms: Classification, Challenges and Future Conceptions.Sensors (Basel, Switzerland) · 2026Review
- Can bionic eyes restore vision? Breakthroughs, challenges, and future frontiers in ophthalmology - A comprehensive review.Journal of biological engineering · 2025Article
- Retinitis Pigmentosa: Novel Therapeutic Targets and Drug Development.Pharmaceutics · 2023Review
- Integrated Low-Voltage Compliance and Wide-Dynamic Stimulator Design for Neural Implantable Devices.Sensors (Basel, Switzerland) · 2023Article
- Computational analysis of efficient organic solar cell-based retinal prosthesis using plasmonic gold nanoparticles.Frontiers in cellular neuroscience · 2023Article
- Nanocone-Array-Based Platinum-Iridium Oxide Neural Microelectrodes: Structure, Electrochemistry, Durability and Biocompatibility Study.Nanomaterials (Basel, Switzerland) · 2022Article
- Factors affecting two-point discrimination in Argus II patients.Frontiers in neuroscience · 2022Article
- Do retinal implants provide long-term efficacy, safety and improve quality of life? A systematic review.Therapeutic advances in ophthalmologyReview
- An update on human visual prosthesis: The Claes H. Dohlman lecture 2025.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo describe the outcomes of patients with retinitis pigmentosa (RP) who received the Argus II Retinal Prosthesis System.
methodsThis retrospective, interventional case series evaluated 10 consecutive patients who received the Argus II retinal implant and underwent visual function tests with the system on and system off. The main outcome measures were safety (the number, seriousness, and relatedness of adverse events), and visual function measured by computer-based objective tests, including square localization (SL) and direction of motion (DOM). Secondary measures included functional vision performance, including orientation and mobility (O&M) tasks.
resultsThere were no intraoperative complications and all prostheses remained implanted at the end of follow up. The mean patient age was 41.3 years; mean duration of the implant in vivo was 2.1 years. One patient had a suture exposure over the coil suture tab and over the inferior case suture tab at 2 years postoperatively, which was managed successfully. One patient developed mild vitreous hemorrhage that resolved spontaneously. One patient developed high intraocular pressure postoperatively due to a tight scleral band (SB) that was managed successfully. Patients performed significantly better with the Argus II system on than off on all tasks.
conclusionPatients who received the Argus II had a safety profile out to 4 years post-implantation that was markedly better than that observed in the pre-approval phase of the Argus II. In this population of RP patients, the Argus II retinal prosthesis provided useful visual function over several years that likely translates into improved quality of life.
trial registrationclinicaltrials.gov identifier, NCT00407602.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.